Estimaciones de analistas de Wall Street para Novavax, Inc. (NVAX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.37 | ||
| 2026-08-06 | $-0.32 | $-0.38 | +15.8% |
| 2026-05-06 | $-0.06 | $-0.25 | +76.0% |
| 2026-02-26 | $0.11 | $-0.66 | +116.7% |
| 2025-11-06 | $-1.25 | $-1.08 | -15.7% |
| 2025-08-06 | $0.62 | $-0.07 | +985.7% |
| 2025-05-08 | $2.93 | $0.71 | +312.7% |
| 2025-02-27 | $-0.51 | $-0.75 | +32.0% |
Ratios de valoración
| Precio / Valor contable | -8.07 |
| EV / EBITDA | -8.51 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $15.4M | $31.2M | $34.3M | $18.7M | $22.4M | $197.6M | $1.60B | $556.4M | $682.2M | $1.12B |
| Coste de Ventas | $237.9M | 0 | 0 | $113.8M | 0 | 0 | $902.6M | $343.8M | $202.7M | $71.1M |
| Beneficio Bruto | -$222.6M | $31.2M | $34.3M | -$95.2M | $22.4M | $197.6M | $696.3M | $212.6M | $479.4M | $1.05B |
| I+D | $237.9M | $168.4M | $173.8M | $113.8M | $747.0M | $2.53B | $1.24B | $737.5M | $391.2M | $336.8M |
| Generales y Administrativos | $46.5M | $34.5M | $34.4M | $34.4M | $145.3M | $298.4M | $488.7M | $468.9M | $337.2M | $150.3M |
| Gastos Operativos | $284.5M | $202.9M | $208.2M | $148.3M | $439.1M | $1.88B | $1.34B | $779.1M | $728.4M | $489.1M |
| Beneficio Operativo | -$269.1M | -$171.7M | -$173.9M | -$120.6M | -$416.7M | -$1.69B | -$644.7M | -$566.5M | -$248.9M | $563.3M |
| EBITDA | -$258.5M | -$159.9M | -$163.0M | -$113.3M | -$398.2M | -$1.68B | -$604.7M | -$487.4M | -$108.0M | $492.3M |
| Gastos por Intereses | $13.0M | $14.1M | $12.2M | $13.6M | $15.1M | $21.1M | $19.9M | $14.4M | $20.1M | $22.5M |
| Beneficio Antes de Impuestos | -$280.0M | -$183.8M | -$184.7M | -$132.7M | -$418.3M | -$1.71B | -$653.6M | -$543.0M | -$176.6M | $442.2M |
| Impuestos | $2.3M | 0 | $1.4M | 0 | 0 | $29.2M | $4.3M | $2.0M | $10.9M | $1.9M |
| Beneficio Neto | -$280.0M | -$183.8M | -$184.7M | -$130.1M | -$418.3M | -$1.74B | -$657.9M | -$545.1M | -$187.5M | $440.3M |
| BPA | $-20.68 | $-12.56 | $-9.99 | $-5.40 | $-7.43 | $-23.44 | $-8.42 | $-5.41 | $-1.23 | $2.72 |
| BPA Diluido | $-20.68 | $-12.56 | $-9.99 | $-5.40 | $-7.43 | $-23.44 | $-8.42 | $-5.41 | $-1.23 | $2.54 |
| Acciones en Circulación (Diluidas) | $13.5M | $14.6M | $18.5M | $24.1M | $57.6M | $74.4M | $78.2M | $100.8M | $152.2M | $173.1M |
Precio
| Precio | $9.35 |
| Capitalización | $1.5B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: CVAC · NKTR · NTLA · ORIC · PGEN · TERN · TRVI
Explorar sector: Healthcare · Biotechnology
Más secciones de NVAX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones